Spero Therapeutics (NASDAQ:SPRO - Get Free Report) is projected to issue its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $43.3390 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.
Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its earnings results on Thursday, March 26th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.73. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%.The company had revenue of $41.30 million during the quarter, compared to analyst estimates of $26.00 million.
Spero Therapeutics Price Performance
Shares of SPRO stock opened at $2.42 on Wednesday. Spero Therapeutics has a 12-month low of $0.57 and a 12-month high of $3.22. The firm has a market capitalization of $140.12 million, a price-to-earnings ratio of 20.17 and a beta of 1.43. The business has a 50 day simple moving average of $2.50 and a 200 day simple moving average of $2.41.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Spero Therapeutics in a report on Tuesday, April 21st. Wall Street Zen raised Spero Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Sunday, March 29th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Reduce".
Check Out Our Latest Report on Spero Therapeutics
Insider Transactions at Spero Therapeutics
In related news, insider Esther Rajavelu sold 87,917 shares of the stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $2.36, for a total value of $207,484.12. Following the completion of the transaction, the insider directly owned 1,012,091 shares of the company's stock, valued at $2,388,534.76. This represents a 7.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.50% of the stock is owned by company insiders.
Institutional Investors Weigh In On Spero Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in Spero Therapeutics in the fourth quarter worth approximately $56,000. Arrowstreet Capital Limited Partnership acquired a new stake in Spero Therapeutics in the third quarter worth approximately $283,000. State Street Corp lifted its position in Spero Therapeutics by 10.1% in the fourth quarter. State Street Corp now owns 210,151 shares of the company's stock worth $490,000 after purchasing an additional 19,200 shares during the period. GSK plc acquired a new stake in Spero Therapeutics in the fourth quarter worth approximately $21,414,000. Finally, Invesco Ltd. acquired a new stake in Spero Therapeutics in the second quarter worth approximately $43,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.
About Spero Therapeutics
(
Get Free Report)
Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.
The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Spero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spero Therapeutics wasn't on the list.
While Spero Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
